Eli Lilly and Company (NYSE:LLY) Trading Up 0.1%

Shares of Eli Lilly and Company (NYSE:LLY) were up 0.1% on Thursday . The stock traded as high as $784.00 and last traded at $775.86. Approximately 714,968 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 3,050,610 shares. The stock had previously closed at $775.00.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Down 0.4 %

The stock has a market cap of $733.28 billion, a price-to-earnings ratio of 113.63, a PEG ratio of 1.45 and a beta of 0.37. The stock has a 50 day simple moving average of $761.56 and a 200 day simple moving average of $675.58. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned $1.62 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.67%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the stock. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the third quarter valued at approximately $27,000. Tidemark LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $29,000. Core Wealth Advisors Inc. lifted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Finally, Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter worth $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.